Holen Sie sich die Stockscreener-App
16.86
0.06%
0.010
Schlusskurs vom Vortag:
$16.85
Offen:
$16.87
24-Stunden-Volumen:
351.56K
Relative Volume:
0.63
Marktkapitalisierung:
$873.82M
Einnahmen:
$109.78M
Nettoeinkommen (Verlust:
$114.54M
KGV:
7.6476
EPS:
2.2046
Netto-Cashflow:
$268.74M
1W Leistung:
+0.00%
1M Leistung:
-0.82%
6M Leistung:
-10.98%
1J Leistung:
+51.08%
1-Tages-Spanne:
$16.85
$16.88
1-Wochen-Bereich:
$16.84
$16.92
52-Wochen-Spanne:
$10.82
$21.03
Theravance Biopharma Inc Stock (TBPH) Company Profile
Firmenname
Theravance Biopharma Inc
Sektor
Branche
Telefon
650-808-6000
Adresse
UGLAND HOUSE, SOUTH CHURCH STREET, GEORGE TOWN, GRAND CAYMAN
Compare TBPH vs VRTX, REGN, ARGX, RVMD, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TBPH
Theravance Biopharma Inc
|
16.86 | 873.82M | 109.78M | 114.54M | 268.74M | 2.2046 |
VRTX
Vertex Pharmaceuticals Inc
|
477.10 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
762.63 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
853.82 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
187.53 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
316.01 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Theravance Biopharma Inc Stock (TBPH) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-05 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2026-03-04 | Herabstufung | B. Riley Securities | Buy → Neutral |
| 2025-12-03 | Eingeleitet | Oppenheimer | Outperform |
| 2025-09-12 | Eingeleitet | B. Riley Securities | Buy |
| 2024-08-06 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-04-12 | Eingeleitet | BTIG Research | Buy |
| 2024-01-08 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-05-23 | Eingeleitet | SVB Leerink | Outperform |
| 2021-11-05 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2021-09-15 | Herabstufung | JP Morgan | Overweight → Underweight |
| 2021-08-25 | Herabstufung | Morgan Stanley | Overweight → Underweight |
| 2021-08-24 | Herabstufung | Cowen | Outperform → Market Perform |
| 2020-10-14 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-07-07 | Eingeleitet | JP Morgan | Overweight |
| 2020-06-15 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2020-05-13 | Eingeleitet | Cowen | Outperform |
| 2020-01-08 | Bestätigt | H.C. Wainwright | Buy |
| 2019-11-06 | Hochstufung | Robert W. Baird | Underperform → Neutral |
| 2019-10-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-03-29 | Fortgesetzt | Piper Jaffray | Overweight |
| 2017-08-17 | Eingeleitet | Evercore ISI | Outperform |
| 2017-06-16 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2017-05-11 | Bestätigt | Needham | Buy |
| 2016-12-21 | Eingeleitet | Needham | Buy |
| 2016-11-03 | Eingeleitet | Piper Jaffray | Overweight |
| 2016-10-12 | Herabstufung | Robert W. Baird | Neutral → Underperform |
| 2016-08-03 | Herabstufung | BofA/Merrill | Neutral → Underperform |
| 2016-06-20 | Eingeleitet | Guggenheim | Buy |
| 2016-06-20 | Bestätigt | Leerink Partners | Outperform |
| 2016-05-12 | Eingeleitet | Leerink Partners | Outperform |
| 2016-05-05 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2015-02-03 | Hochstufung | Robert W. Baird | Underperform → Neutral |
Alle ansehen
Theravance Biopharma Inc Aktie (TBPH) Neueste Nachrichten
ETFs Investing in Theravance Biopharma Inc Stocks - TradingView
Theravance Biopharma Inc (TBPH) Cash Flow - TradingKey
TBPH|Theravance Biopharma Inc|Price:16.865|Chg%:+0.005 - TradingKey
Theravance Biopharma Inc (TBPH) Balance Sheet - TradingKey
Theravance Biopharma Inc (TBPH) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Theravance Biopharma Inc (TBPH) Institutional Confidence - TradingKey
Theravance Biopharma Inc (TBPH) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Theravance Biopharma Inc Revenue Breakdown – FWB:0TB - TradingView
Theravance Biopharma Inc Revenue Breakdown – LS:A1137V - TradingView
Theravance Biopharma Inc (TBPH) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Theravance Biopharma Inc (TBPH) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Liquidity Mapping Around (TBPH) Price Events - Stock Traders Daily
Zymeworks Won’t Host Q2 Call Amid Proposed Theravance Deal - Stock Titan
Zymeworks to report Q2 2026 results on August 6, no earnings call due to Theravance Biopharma acquisition plans - Pluang
Theravance Biopharma (TBPH) Hovers Near Support Amidst Quiet Trading SessionProtective Put - dars.gov.et
Are TBPH, IRDM, LCII, PATK Obtaining Fair Deals for their Shareholders? - Finansavisen
Theravance stock down 3% after Zymeworks announces buyout - MSN
TBPH Stock Alert: Halper Sadeh LLC is Investigating Whether Theravance Biopharma, Inc. is Obtaining a Fair Price for its Shareholders - AOL.com
Theravance Biopharma Price Target Raised to $17.00/Share From $15.00 by HC Wainwright & Co. - Moomoo
H.C. Wainwright Downgrades Theravance Biopharma(TBPH.US) to Hold Rating, Raises Target Price to $17 - Moomoo
Zymeworks' $929 Million Pivot: How a COPD Acquisition Redefines Its Future - Kavout | AI
TBPHTheravance Biopharma Inc Options - Finviz
If You Invested $1,000 in Theravance Bioph (TBPH) - Stock Titan
Arthur Cox advises on pharmaceutical sector acquisition - ICLG
Theravance Biopharma Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Positive SurpriseEarnings Season Review - dars.gov.et
TBPH News | THERAVANCE BIOPHARMA INC (NASDAQ:TBPH) - ChartMill
Zymeworks to pay $17/share for Theravance Biopharma in $929M deal - MSN
Theravance Biopharma Insider Sold Shares Worth $5,791,555, According to a Recent SEC Filing - marketscreener.com
Theravance Biopharma(TBPH.US) 10% Shareholder Sells US$5.79 Million in Common Stock - Moomoo
Funds tied to Eli Samaha trim Theravance Biopharma (TBPH) stake in open-market sales - Stock Titan
Here’s Why Zymeworks Inc. Paid $929M For Theravance Biopharma (NASDAQ:ZYME) - Seeking Alpha
TBPH SEC FilingsTheravance Bioph 10-K, 10-Q, 8-K Forms - Stock Titan
Arthur Cox advises Theravance Biopharma on its $929 million merger with Zymeworks - Arthur Cox LLP
Zymeworks to Acquire Theravance Biopharma in $929 Million Transaction - Global Legal Chronicle
Canadian Zymeworks acquires American Theravance Biopharma for $929 million - AKM.RU
After a three-decade legacy, Theravance agreed to a complex sale for less than $1 billion - The Business Journals
Theravance Stock Down 3% After Zymeworks Announces Buyout - Yahoo Finance
Press Release: Zymeworks to Acquire Theravance Biopharma, Inc. - Moomoo
Zymeworks agrees to buy Theravance Biopharma for $929m - Pharmaceutical Technology
TBPH Downgraded by BTIG -- Rating Changed to Neutral - GuruFocus
Vancouver biotech Zymeworks buying Theravance for US$929M - Castanet
Zymeworks to Acquire Theravance Biopharma, Inc. - Indovizka.com
Zymeworks Inc to Acquire Theravance Biopharma Inc Transcript - GuruFocus
Zymeworks offers US$929-million for COPD drug maker Theravance - The Globe and Mail
Zymeworks to buy Theravance Biopharma in $929M deal – a look at what this deal means for TBPH shareholders - MSN
Zymeworks Buys Theravance To Execute On New Business Strategy - insights.citeline.com
Theravance Biopharma (TBPH) Downgraded to Hold Following $929M A - GuruFocus
Theravance downgraded at Jones on Zymeworks acquisition - MSN
Are IRDM, TBPH, SYNA, TECH Obtaining Fair Deals for their Shareh - GuruFocus
Are IRDM, TBPH, SYNA, TECH Obtaining Fair Deals for their Shareholders? - Finviz
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Theravance Biopharma, Inc. (NASDAQ: TBPH) - PR Newswire
Finanzdaten der Theravance Biopharma Inc-Aktie (TBPH)
Umsatz
Nettogewinn
Free Cashflow
ENV
Theravance Biopharma Inc-Aktie (TBPH) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Samaha Eli | 10% Owner |
Jul 01 '26 |
Sale |
17.00 |
37,799 |
642,628 |
9,174,453 |
| Samaha Eli | 10% Owner |
Jun 30 '26 |
Sale |
17.13 |
25,027 |
428,788 |
9,212,252 |
| Farnum Rhonda | SVP, COMM & MEDICAL AFFAIRS |
Jun 15 '26 |
Sale |
16.39 |
13,314 |
218,167 |
232,457 |
2.44%
0.02%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):